Lecinoxoids: Unique, Orally Available Investigational Drugs for Treatment of
Immune-Inflammatory Disorders

VBL’s proprietary Lecinoxoid platform technology comprises a family of orally administered small molecules designed to modulate the body’s inflammatory response. Lecinoxoids are compounds that are structurally and functionally similar to naturally occurring molecules, known as oxidized phospholipids, which possess immune modulating anti-inflammatory proprieties, modified to enhance stability and activity. 

The Lecinoxoid platform technology seeks to harness the ability of oxidized phospholipids to regulate and attenuate key immune-inflammatory signaling.

Lecinoxoids mimic the structure of oxidized phospholipid molecules and are synthetically manipulated to increase their stability and ability to target specific receptors.

Lecinoxoids have the potential to act through two specific mechanisms:

  1.  The inhibition of cellular signaling cascades associated with the innate immune system, known as toll-like receptor, or TLR, signaling. 
  2.  The inhibition of the migration of monocytes toward chemoattractants present in areas of inflammation.

The lead anti-inflammatory product candidate from our Lecinoxoid platform technology, VB-201, demonstrated proof of concept in a Phase 2 study for vascular inflammation.